ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

The SELECT trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (DM), to those without DM. In this interview, Abraham Lincoff, MD, FACC, and Glenn A. Hirsch MD, MHS, FACC, discuss AHA Late-Breaker: SELECT – Semaglutide and Cardiovascular Outcomes in Patients with...

In this review, authors discuss how multimodality imaging can help to evaluate the left ventricular remodeling response and improve risk stratification in patients with moderate aortic stenosis.  

In this interview, Jeroen J Bax, MD, PhD, FACC, and Matt Cavender, MD, MPH, FACC, discuss JACC review, Managing Patients

In this interview, Andrew Kates, MD, FACC, and Alison L. Bailey, MD, FACC, discuss the top takeaways in general cardiology from 2023 including ARAMIS, ORBITA-2, and STOP-CA trials. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

While we know that statin treatment reduces the risk of stroke, heart attack and heart deaths in people at moderate-to-high risk, or with high cholesterol, in REPRIEVE statins decreased the risk in those at low-to-moderate risk, and with 'normal' cholesterol levels who would not usually be considered candidates...